QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 citigroup-maintains-buy-on-kymera-therapeutics-raises-price-target-to-80

Citigroup analyst Geoff Meacham maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $60 ...

 oppenheimer-maintains-outperform-on-kymera-therapeutics-raises-price-target-to-63

Oppenheimer analyst Jeff Jones maintains Kymera Therapeutics (NASDAQ:KYMR) with a Outperform and raises the price target fro...

 truist-securities-maintains-buy-on-kymera-therapeutics-raises-price-target-to-68

Truist Securities analyst Srikripa Devarakonda maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price t...

 hc-wainwright--co-maintains-buy-on-kymera-therapeutics-raises-price-target-to-70

HC Wainwright & Co. analyst Andrew S. Fein maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price t...

 kymera-advances-oral-stat6-degrader-toward-phase-2b-trials-in-atopic-dermatitis-and-asthma-after-positive-early-data-set-for-late-breaking-presentations-at-major-european-medical-conferences

Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecul...

 barclays-initiates-coverage-on-kymera-therapeutics-with-overweight-rating-announces-price-target-of-60

Barclays analyst Etzer Darout initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Overweight rating and announces...

 rbc-capital-initiates-coverage-on-kymera-therapeutics-with-outperform-rating-announces-price-target-of-70

RBC Capital analyst Brian Abrahams initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Outperform rating and anno...

 kymera-therapeutics-q2-eps-095-misses-084-estimate-sales-11476m-miss-21214m-estimate

Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of...

 synovus-financial-gilead-sciences-and-more-on-cnbcs-final-trades

Insights from strategists and analysts can greatly influence market sentiment and investment strategies. CNBC's Halftime Re...

 oppenheimer-maintains-outperform-on-kymera-therapeutics-lowers-price-target-to-53

Oppenheimer analyst Jeff Jones maintains Kymera Therapeutics (NASDAQ:KYMR) with a Outperform and lowers the price target fro...

 wells-fargo-maintains-overweight-on-kymera-therapeutics-lowers-price-target-to-53

Wells Fargo analyst Derek Archila maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and lowers the price target ...

 hc-wainwright--co-maintains-buy-on-kymera-therapeutics-raises-price-target-to-60

HC Wainwright & Co. analyst Andrew Fein maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price targ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION